Drug profile

The FDA adverse-event record for Chondroitin Sulfate + Glucosamine

18 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Chondroitin Sulfate + Glucosamine. See the species affected, top reactions, and outcomes below.

18
adverse-event reports
11.1%
death-coded share
Dog
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
2
Deaths Reported
11.1%
Death Rate

Active Ingredients

Chondroitin SulfateChondroitin Sulfate + GlucosamineGlucosamine

Administration Routes

UnknownOral

Species Affected

Dog 17
Cat 1

Most Affected Breeds

Beagle 2
Boxer (German Boxer) 2
Retriever - Labrador 2
Dog (unknown) 2
Shepherd Dog - German 1
Sheepdog - Polish Lowland 1
Crossbred Canine/dog 1
Cat (unknown) 1
Sheepdog - Long-haired Pyrenean 1
Siberian Husky 1

Most Reported Reactions

Vomiting 5
Diarrhoea 4
Behavioural disorder NOS 3
Not eating 2
Drinking a lot 2
Decreased appetite 2
Lethargy (see also Central nervous system depression in Neurological) 2
Muscle spasm NOS 2
Tremor 2
Bruising 2
Central nervous system disorder NOS 2
Urinary tract infection 1

Outcome Breakdown

Outcome Unknown
6 (33.3%)
Recovered/Normal
5 (27.8%)
Ongoing
5 (27.8%)
Euthanized
1 (5.6%)
Died
1 (5.6%)

Chondroitin Sulfate + Glucosamine Adverse Event Insights

18 reports name Chondroitin Sulfate + Glucosamine; 2 recorded a death outcome (11.1% of reported events, not a population-level mortality rate). Active ingredients: Chondroitin Sulfate, Chondroitin Sulfate + Glucosamine, Glucosamine. Administration routes: Unknown, Oral.

By species: Dog (17 reports), Cat (1 reports). By breed: Beagle (2), Boxer (German Boxer) (2), Retriever - Labrador (2).

Leading clinical signs: Vomiting (5), Diarrhoea (4), Behavioural disorder NOS (3), Not eating (2). Outcome, 18 coded reports: Outcome Unknown leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.